D.V. PECHKUROV, A.A. TYAZHEVA

 Samara State Medical University, Samara

  Contact details:

Pechkurov D.V. — MD, Professor, Head of the Department of Children’s Diseases

Address: 89 Chapaevskaya St., Samara, Russian Federation, tel.: +7 (846) 959-45-11, e-mail: dmpechkurov@yandex.ru

Bile acid diarrhea is a common but poorly understood cause of chronic diarrhea. In this regard, many questions remain regarding its diagnosis and treatment approaches. The article presents an analysis of the available literature data on the possible mechanisms of bile acid diarrhea. The role of complex molecular mechanisms in bile acid circulation, including the farnesoid X-receptor (FXR) and the fibroblast growth factor 4 receptor (FGFR4), is shown. Understanding these mechanisms opens up new possibilities for the diagnosis of this pathology, including the prospects for using new molecular markers. The article also discusses the treatment options for chologenic diarrhea. The presented data serve as a basis to develop strategies for the examination of patients with suspected malabsorption of bile acids.

Key words: chologenic diarrhea, bile acid diarrhea, malabsorption of bile acids, bile acids, diarrhea.

REFERENCES

1. Hofmann A.F., Small D. Detergent properties of bile salts: correlation with physiological function. Annu. Rev. Med, 1967, vol. 18, pp. 333-376.
2. Vijayvargiya P., Camilleri M. Current practice in the diagnosis of bile acid diarrhea. Gastroenterology, 2019, vol. 156 (5), pp. 1233-1238. DOI: 10.1053/j.gastro.2018.11.069
3. Wedlake L., A’Hern R., Russell D. et al. Systematic review: The prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther, 2009, vol. 30, p. 707-717. DOI: 10.1111/j.1365-2036.2009.04081
4. Sadowski D.C., Camilleri M., Chey W.D. et al. Canadian Association of gastroenterology clinical practice guideline on the management of bile acid diarrhea. Clin. Gastroenterol. Hepatol, 2020, vol. 18, pp. 24-41.e1. DOI: 10.1016/j.cgh.2019.08.062
5. Mottacki N., Simrén M., Bajor A. Review article: bile acid diarrhoea — pathogenesis, diagnosis and management. Aliment. Pharmacol. Ther, 2016, vol. 43 (8), pp. 884-898. DOI: 10.1111/apt.13570
6. Thomas J.P., Modos D., Rushbrook S.M. et al. The emerging role of bile acids in the pathogenesis of inflammatory bowel disease. Front. Immunol, 2022, vol. 13. 829525. DOI: 10.3389/fimmu.2022.829525
7. Chang C., Jiang J., Sun R. et al. Downregulation of serum and distal ileum fibroblast growth factor19 in bile acid diarrhea patients. Dig. Dis. Sci, 2021. DOI: 10.1007/s10620-021-07042-x
8. Marasco G., Cremon C., Barbaro M.R. et al. Pathophysiology and clinical management of bile acid diarrhea. J. Clin. Med, 2022, vol. 11 (11), p. 3102. DOI: 10.3390/jcm11113102
9. Schumacher J.D., Guo G.L. Pharmacologic modulation of bile Acid-FXR-FGF15/FGF19 pathway for the treatment of nonalcoholic steatohepatitis. Handb. Exp. Pharmacol, 2019, vol. 256, pp. 325-357. DOI: 10.1007/164_2019_228
10. Piglionica M., Cariello M., Moschetta A. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19. Curr. Opin. Pharmacol, 2018, vol. 43, pp. 93-98. DOI: 10.1016/j.coph.2018.08.005
11. Walters J.R.F., Tasleem A.M., Omer O.S. et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin. Gastroenterol. Hepatol, 2009, vol. 7, pp. 1189-1194. DOI: 10.1016/j.cgh.2009.04.024
12. Wilson A., Almousa A., Teft W.A., Kim R.B. Attenuation of bile acid-mediated FXR and PXR activation in patients with crohn’s disease. Sci. Rep, 2020, vol. 10, p. 1866. DOI: 10.1038/s41598-020-58644-w
13. Duboc H., Rajca S., Rainteau D. et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut, 2013, vol. 62, pp. 531-539. DOI: 10.1136/gutjnl-2012-302578
14. Van den Bossche L., Borsboom D. et al. Tauroursodeoxycholic acid protects bile acid homeostasis under inflammatory conditions and dampens crohn’s disease-like ileitis. Lab. Investig. J. Tech. Methods Pathol 2017, vol. 97, pp. 519-529. DOI: 10.1038/labinvest.2017.6
15. Johnston I.M., Nolan J.D., Pattni S.S. et al. Characterizing factors associated with differences in FGF19 blood levels and synthesis in patients with primary bile acid diarrhea. Am. J. Gastroenterol, 2016, vol. 111, pp. 423-432.
16. Wingender G., Sag D., Kronenberg M. NKT10 cells: a novel iNKT cell subset. Oncotarget. — 2015. — vol. 6. — pp. 26552-26553. DOI: 10.18632/oncotarget.5270
17. Schote A.B., Turner J.D., Schiltz J. et al. Nuclear receptors in human immune cells: expression and correlations. Mol. Immunol. — 2007. — vol. 44. — pp. 1436-1445. DOI: 10.1016/j.molimm.2006.04.021
18. Fiorucci S., Biagioli M., Zampella A., Distrutti E. Bile acids activated receptors regulate innate immunity. Front. Immunol, 2018, vol. 9, p. 1853. DOI: 10.3389/fimmu.2018.01853
19. Massafra V., Ijssennagger N., Plantinga M. et al. Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis. Biochim. Biophys. Acta BBA — Mol. Basis Dis, 2016, vol. 1862, pp. 166-173. DOI: 10.1016/j.bbadis.2015.11.001
20. Walters J.R.F., Tasleem A.M., Omer O.S., Brydon W.G., Dew T., le Roux C.W. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin. Gastroenterol. Hepatol, 2009, vol. 7. — pp. 1189-1194.
21. Soldavini J., Kaunitz J.D. Pathobiology and potential therapeutic value of intestinal short-chain fatty acids in gut inflammation and obesity. Dig. Dis. Sci, 2013, vol. 58, p. 2756-2766. DOI: 10.1007/s10620-013-2744-4
22. Ridlon J.M., Kang D.J., Hylemon P.B. Metabolism of oxo-bile acids and characterization of recombinant 12α-hydroxysteroid dehydrogenases from bile acid 7α-dehydroxylating human gut bacteria. Appl. Environ. Microbiol, 2018, vol. 84. e00235-18. DOI: 10.1128/AEM.00235-18
23. Das P., Marcišauskas S., Ji B., Nielsen J. Metagenomic analysis of bile salt biotransformation in the human gut microbiome. BMC Genomics, 2019, vol. 20, p. 517. DOI: 10.1186/s12864-019-5899-3
24. Guzior D.V., Quinn R.A. Review: microbial transformations of human bile acids. Microbiome, 2021, vol. 9, p. 140. DOI: 10.1186/s40168-021-01101-1
25. Sayin S.I., Wahlström A., Felin J. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell. Metab, 2013, vol. 17, pp. 225–235. DOI: 10.1016/j.cmet.2013.01.003
26. Farrugia A., Arasaradnam R. Bile acid diarrhoea: pathophysiology, diagnosis and management. Front. Gastroenterol, 2020, vol. 12 (6), pp. 500-507. DOI: 10.1136/flgastro-2020-101436
27. Larabi A.B., Masson H.L.P., Bäumler A.J. Bile acids as modulators of gut microbiota composition and function. Gut. Microbes, 2023, vol. 15 (1). 2172671. DOI: 10.1080/19490976.2023.2172671
28. Camilleri M., Carlson P., BouSaba J. et al. Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhea. Gut, 2023, vol. 72, pp. 54-65. DOI: 10.1136/gutjnl-2022-327471
29. Perwaiz S., Mignault D., Tuchweber B., Yousef I.M. Rapid and improved method for the determination of bile acids in human feces using MS. Lipids, 2002, vol. 37 (11), pp. 1093-1100. DOI: 10.1007/s11745-002-1005-0
30. Baumgartner M., Lang M., Holley H. et al. mucosal biofilms are an endoscopic feature of irritable Bowel syndrome and ulcerative colitis. Gastroenterology, 2021, vol. 161 (4), pp. 1245-1256.e20. DOI: 10.1053/j.gastro.2021.06.024
31. Zhan K., Zheng H., Li J., Wu H. et al. Gut microbiota-bile acid crosstalk in diarrhea-irritable Bowel syndrome. Biomed. Res. Int, 2020, vol. 2020. 3828249. DOI: 10.1155/2020/3828249
32. Dior M., Delagrèverie H., Duboc H. et al. Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. Neurogastroenterol. Motil, 2016, vol. 28, pp. 1330–1340.
33. Sadowski D.C., Camilleri M., Chey W.D. et al. Canadian Association of gastroenterology clinical practice guideline on the management of bile acid diarrhea. Clin. Gastroenterol. Hepatol, 2020, vol. 18 (1), pp. 24-41.e1. DOI: 10.1016/j.cgh.2019.08.062
34. Sauter G.H., Münzing W., von Ritter C. et al. Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum. Dig. Dis. Sci, 1999, vol. 44, pp. 14-19.
35. Borup C., Vinter-Jensen L., Jørgensen S.P.G. et al. Prospective comparison of diagnostic tests for bile acid diarrhoea. Aliment. Pharmacol. Ther, 2024, vol. 59 (1), pp. 39–50. DOI: 10.1111/apt.17739
36. Kurien M., Evans K.E., Leeds J.S. et al. Bile acid malabsorption: An under-investigated differential diagnosis in patients presenting with diarrhea predominant irritable bowel syndrome type symptoms. Scand. J. Gastroenterol, 2011, vol. 46 (7-8), pp. 818-822. DOI: 10.3109/00365521.2011.574728
37. Sciarretta G., Fagioli G., Furno A. 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhea and its correlation with small bowel transit. Gut, 1987, vol. 28, pp. 970-975.
38. Riemsma R. Al M., Corro Ramos I. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis. Health Technol. Assess, 2013, vol. 17, pp. 1-236.
39. Reid F., Peacock J., Coker B. A multicenter prospective study to investigate the diagnostic accuracy of the SeHCAT test in measuring bile acid malabsorption: research protocol. JMIR Res. Protoc, 2016, vol. 5, p. e13. DOI: 10.2196/resprot.4467
40. Wedlake L., A’Hern R., Russell D. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther, 2009, vol. 30 (7), pp. 707-717. DOI: 10.1111/j.1365-2036.2009.04081
41. Camilleri M. BAD on the runs: improved diagnosis of idiopathic bile acid diarrhea. Dig. Dis. Sci, 2021. DOI: 10.1007/s10620-021-07044-9
42. Montagnani M., Love M.W., Rossel P. et al. Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption. Scand. J. Gastroenterol, 2001, vol. 36, pp. 1077-1080. DOI: 10.1080/003655201750422693
43. Novikova V.P., Belousova L.N. Chologenic diarrhea: from diagnosis to treatment. Voprosy detskoy dietologii, 2020, vol. 18 (5), pp. 36-41 (in Russ.). DOI: 10.20953/1727-5784-2020-5-36-41
44. Vijayvargiya P., Camilleri M., Carlson P. et al. Effects of colesevelam on bowel symptoms, biomarkers, and colonic mucosal gene expression in patients with bile acid diarrhea in a randomized trial. Clin. Gastroenterol. Hepatol, 2020, vol. 18, pp. 2962-2970.e6.
45. Beigel F., Teich N., Howaldt S. et al. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn’s disease: A randomized, double-blind, placebo-controlled study. J. Crohn’s Colitis, 2014, vol. 8 (11), pp. 1471-1479. DOI: 10.1016/j.crohns.2014.05.009
46. Borup C., Vinter-Jensen L., Jørgensen S.P.G. et al. Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial. Lancet Gastroenterol. Hepatol, 2023, vol. 8, pp. 321-331. DOI: 10.1016/S2468-1253(22)00401-0
47. Kamar F.B., McQuillan R.F. Hyperchloremic metabolic acidosis due to cholestyramine: a case report and literature review. Case Rep. Nephrol, 2015, vol. 2015. 309791. DOI: 10.1155/2015/309791
48. Walters J.R.F., Johnston I.M., Nolan J.D. et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment. Pharmacol. Ther, 2014, vol. 41, pp. 54-64. DOI: 10.1111/apt.12999
49. Mroz M.S., Keating N., Ward J.B. et al. Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo. Gut, 2013, vol. 63, pp. 808-817. DOI: 10.1136/gutjnl-2013-305088
50. Solis A.G., Klapholz M., Zhao J., Levy M. The bidirectional nature of microbiome-epithelial cell interactions. Curr. Opin. Microbiol, 2020, vol. 56, pp. 45-51. DOI: 10.1016/j.mib.2020.06.007